TA Buchholz, TL Walden, BR Prestidge [ MD Anderson Cancer Ctr, Houston; Natl Cancer Inst, Bethesda, Md; Wilford Hall Med Ctr, Lackland AFB, Tex]
Cost-Effectiveness of Posttreatment Surveillance After Radiation Therapy for Early Stage Seminoma
Cancer 82: 1126-1133, 1998
Conclusion – Nearly all patients with early-stage seminoma who undergo orchiectomy and postoperative lymph node irradiation have excellent disease-free and overall survival rates. Thus, the cost of surveillance, as carried out in this patient group, does not appear to be justified. An analysis of patterns of failure may lead to a more appropriate follow-up schedule. Singificant cost savings can be achieved by eliminating surveillance CT scans and limiting serum studies to selected patients.
Tognini PG, Foster RS, McGraw P, et al [Indiana Univ, Indianapolis]
Combined Post-Chemotherapy retroperitoneal Lymph Node Dissection and Resection of Chest Tumor Under the Same anesthetic is Appropriate Based on Morbidity and Tumor Pathology
J Urol 159: 1833-1835,1998
One hundred forty three patients were reviewed retrospectively.
Conclusion : The authors demonstrate that this approach is feasible and does not place the patient at undue risk for complications.
Patients who are undergoing postchemotherapy retroperitoneal lymphadenectomy for uncomplicated indications do not need to undergo excision of the chest lesions if the retroperitoneal resection demonstrates necrosis.
In that situation the residual chest abnormalities may be monitored.
“Uncomplicated” are those patients who have normal tumor markers who have received the standard 1st line chemotherapy.
S. Baltaci, D. Orhan, K. Turkolmez, C. Yesilli, Y. Beduk and O. Tulunay (Departments of Urology and Pathology, University of Ankara School of Medicine, Ankara, Turkey)
P53, bcl-2 and bax Immunoreactivity as Predictors of Response and Outcome after Chemotherapy for Metastatic Germ Cell Testicular Tumours
BJU Intl. May 2001 Vol. 87 (7) Pg. 661-666
Conclusion : The incidence of P53 and bax immunoreactivity in testicular GCTs is higher than that of bcl-2 immunoreactivity.
However, only P53 immunoreactivity could be used to predict the response to chemotherapy. P53, bcl-2 and bax scores were not significant prognostic factors for survival after chemotherapy.